<div id="readability-page-1"><div>Maetzold Derek J Chief Executive Officer of Castle Biosciences Inc [CSTL] filed a Form 4 on December 11, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:<div><table><tbody><tr><th>Date</th><th>Transaction</th><th>Shares</th><th>Price</th><th>Value</th></tr><tr><td>12/9/25-12/10/25</td><td>Exercise</td><td>48,919</td><td>$0.00</td><td>N/A</td></tr><tr><td>12/9/25-12/10/25</td><td>Surrender(1)</td><td>19,251</td><td>$38.18</td><td>$734,955</td></tr></tbody></table></div>Ending Holdings: 328,587 (67,215 - Direct, 261,372 - Indirect)<ul><li>(1)</li><li>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</li></ul>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data. </div></div>

CSTL

CEO Derek J. Maetzold of Castle Biosciences Inc acquired 29,668 shares, as disclosed in a Form 4 filed with the SEC on December 11, 2025. The transaction involved exercising 48,919 shares and surrendering 19,251 shares at $38.18 each to cover option exercise costs and tax liabilities. Maetzold's ending holdings are 328,587 shares, with 67,215 held directly and 261,372 indirectly.

CEO Maetzold Acquires 29,668 Of Castle Biosciences Inc [CSTL]